🇺🇸

US SEC Filing Intelligence

· daily

S&P 500 Financials Sector SEC Filings — July 27, 2026

This digest covers 5 filings from S&P 500 Financials constituents, all with enriched insider trading data. A notable cluster of insider selling is evident, with high-level executives at Travelers (2 EVPs), Progressive (CIO), and Truist (Director) all reducing equity exposure. The lack of any buy-side activity paints a uniformly bearish insider sentiment across the subsector, suggesting management may see current valuations as full or headwinds building at the company level. In isolation, Travelers’ two distinct insider sales (both C-suite, totaling ~$4.4M) are the most material events, as they are linked to option exercises and multi-million dollar share disposals. The Goldman Sachs preferred stock filing (Series AA) is capital-neutral but adds fixed-income supply, pointing to ongoing balance-sheet management. No period-over-period comparisons, forward-looking guidance, or capital allocation changes were present in the enriched data, limiting sector-wide trend analysis. Overall, the dominant theme is insider de-risking by bank and insurance executives, which warrants close monitoring for further signs of fundamental deterioration.

5 high priority 5 total filings
· daily

S&P 500 Energy Sector SEC Filings — July 27, 2026

The S&P 500 Energy sector is showing a bifurcated picture: Baker Hughes (BKR) demonstrates robust operational execution in its Industrial & Energy Technology (IET) segment, with record orders and RPO, yet faces headwinds from declining GAAP earnings and flat OFSE backlog, resulting in a mixed sentiment. Expand Energy's acquisition of Twin Eagle signals strategic consolidation in the midstream space, though the lack of financial details creates uncertainty. Insider activity is minimal, with only a nominal buy at Texas Pacific Land Corp (TPL), but a significant passive stake accumulation by JPMorgan in BKR (6.9%) suggests institutional confidence. Period-over-period data reveals margin improvement at BKR (adjusted EBITDA +6% QoQ) despite revenue declines, pointing to cost discipline. The sector's capital allocation focus remains on growth investments (BKR's RPO surge) and strategic M&A (Expand Energy), with no dividend or buyback changes noted in the filings. The key portfolio-level theme is the divergence between traditional oilfield services (flat/declining) and energy transition/industrial technology (strong growth), which investors should monitor for relative performance.

2 high priority 3 medium 5 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — July 27, 2026

The three Consumer Staples filings reveal a sector bifurcated between defensive insider buying and governance tightening. McCormick's director purchase signals confidence in the non-voting share class at a $50.21 entry point, contrasting with Hershey's 10% owner executing a routine $1.4M sale under a 10b5-1 plan, which is a neutral-to-negative signal given the trust's structural selling. Kraft Heinz's bylaw amendments raising the special meeting threshold to 20% represent a defensive governance move to insulate management from activist pressure, a growing trend in the sector. No period-over-period financial trends or forward-looking guidance were disclosed in these filings, limiting trend analysis. The key actionable insight is the divergence in insider behavior: McCormick's director is betting on value, while Hershey's largest holder continues a pre-planned liquidation. The sector's capital allocation and operational metrics remain opaque from these specific filings, but the governance shift at Kraft Heinz warrants monitoring for potential shareholder activism.

3 high priority 3 total filings
· daily

S&P 500 Industrials Sector SEC Filings — July 27, 2026

The latest batch of 9 filings for the S&P 500 Industrials stream reveals a sector dominated by passive institutional ownership and routine insider compensation, punctuated by notable insider selling at two key transportation and industrial conglomerate names. JPMorgan Chase and BlackRock have filed amended 13Gs for Trane Technologies, 3M, and Carrier Global, confirming their significant passive stakes (5.6% to 7.6%) and signaling stable, non-activist positions. The most actionable signals come from insider trading activity: senior executives at CSX Corp and General Electric have executed significant stock sales, with the CSX VP & CAO selling nearly all of his direct holdings and a GE SVP cashing in on a low-cost option exercise. These sales, occurring at or near 52-week highs for both companies, raise a cautionary flag about management's view of current valuations. Conversely, routine phantom stock unit awards to Caterpillar executives suggest a standard compensation alignment with long-term performance. The overall theme is one of capital returns and management confidence being tested by insider profit-taking, with no major guidance changes or M&A catalysts in this batch.

5 high priority 4 medium 9 total filings
· daily

US Material Events SEC 8-K Filings — July 27, 2026

This Material Events Monitor digest covers 50 filings from July 27, 2026, revealing a market dominated by aggressive M&A and strategic capital allocation, particularly in the biotech and energy sectors. The most significant development is argenx's $2.2 billion acquisition of Forte Biosciences, signaling a major bet on the autoimmune pipeline, while Lattice Semiconductor's acquisition of AMI targets data center AI growth. A clear sector theme is the wave of auditor changes tied to the AES Corp. merger, with three subsidiaries switching from EY to KPMG, a procedural but notable event. Several companies are aggressively refinancing to lower costs and extend maturities, including Somnigroup ($2.9B) and Target Hospitality ($660M), while others like Glucotrack and Ocean Power Technologies are resorting to dilutive debt-to-equity conversions and ATM offerings, highlighting a bifurcation in financial health. Insider activity is sparse, but the CEO succession at Cracker Barrel and the new CEO appointment at Power Solutions International are key leadership events to watch. Overall, the market is showing strong conviction in high-growth areas through M&A, while some smaller caps face liquidity and governance challenges.

50 high priority 50 total filings
· daily

Insider Trading Pulse — July 27, 2026

The July 27, 2026, insider trading digest reveals a bifurcated market with significant insider selling at large-cap industrial and financial firms, contrasted by strategic insider buying in select small-cap and special situation names. The most notable bearish signal is a concentrated wave of large-scale, pre-planned sales by directors at Enerpac Tool Group and a massive $2.32M sale by a Roper Technologies director. On the bullish side, a $25M investment by the Abu Dhabi Investment Authority into Jefferies Credit Partners BDC stands out as a strong institutional vote of confidence. A major corporate event is unfolding at Taylor Morrison Home Corp, where three directors collectively disposed of over $10.7M in deferred stock units, likely tied to a merger or acquisition. The data also shows routine option exercises and tax-withholding sales at USANA Health Sciences and Leggett & Platt, which are neutral from a conviction standpoint. The overall theme is one of caution at the top, with insiders at several high-quality companies monetizing equity, while value-oriented and event-driven plays attract capital.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — July 27, 2026

The July 27, 2026, filing batch for the Dow 30 reveals a mixed picture of insider conviction and capital structure activity. The most significant actionable signals come from two senior Travelers executives who collectively sold over $4.3 million in stock after exercising options, a bearish signal that warrants close monitoring. In contrast, Caterpillar's CEO and CFO received phantom stock awards, aligning management with long-term shareholder value. Goldman Sachs created a new $2.5 billion preferred stock series, signaling a strategic capital raise likely for regulatory or balance sheet optimization. A 13G filing from JPMorgan shows a passive 7.4% stake in 3M, indicating institutional confidence without activist intent. No period-over-period comparisons or forward-looking guidance were available in these filings, limiting trend analysis. The overall theme is one of insider profit-taking at Travelers, capital management at Goldman, and routine compensation alignment at Caterpillar, with no sector-wide patterns emerging from this small sample.

6 high priority 1 medium 7 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — July 27, 2026

The July 27, 2026, corporate distress landscape is dominated by acute delisting threats across three micro-cap companies, signaling a severe liquidity and market access crisis in the sector. AMASS Brands and Nexalin Technology both received Nasdaq deficiency notices, with Nexalin facing an imminent trading suspension on August 4, 2026, unless a hearing panel intervenes. Picard Medical, while also in distress with negative stockholders' equity, has secured a temporary reprieve via an accepted NYSE American compliance plan, offering a potential turnaround path. Period-over-period data reveals a stark contrast in financial trajectories: Nexalin's revenue declined 12% YoY with gross margins compressing 300 bps, while Picard Medical's revenue grew 8% YoY but was offset by a 15% YoY increase in operating losses. No insider trading activity was reported across the three filings, suggesting management may be constrained by lock-ups or a lack of confidence. The overarching theme is a binary risk-reward profile for distressed micro-caps, where regulatory forbearance is the only lifeline separating continued listing from a catastrophic delisting event.

3 high priority 3 total filings
· daily

Global High-Priority Regulatory Events — July 27, 2026

This digest covers 38 filings from July 27, 2026, dominated by corporate insolvencies, M&A activity, and delisting events. A clear theme is the acceleration of de-SPAC failures, with International Media Acquisition Corp. running low on extensions and Churchill Capital Corp IX delisting, while Future Vision II Acquisition Corp. faces a massive 65% shareholder redemption despite deal approval. The M&A landscape is bifurcated: strategic acquisitions like Lattice Semiconductor's AMI deal and Novanta's Riverpoint Medical purchase are expected to be immediately accretive, while other deals like Genco Shipping's failed takeover and AiRWA's pivot into trade highlight execution risk. Insolvency proceedings are advancing for Pradhin Limited and Simbhaoli Sugars, with the latter's CIRP resuming after a stay was vacated. Regulatory actions include a small RBI penalty on a cooperative bank and Nasdaq delisting threats for AMASS Brands and Nexalin Technology. Overall, the period shows heightened event risk in SPACs and small caps, contrasted with disciplined capital deployment by larger firms.

38 high priority 38 total filings
· daily

US SEC Filings Daily Market Digest — July 27, 2026

Today's digest reveals a market bifurcated between aggressive capital deployment and mounting regulatory/operational risks. The most significant theme is a wave of transformative M&A and strategic pivots, highlighted by argenx's $2.2B acquisition of Forte Biosciences (86% premium) and NIMU's pivot to space via Gravitics. However, this activity is juxtaposed against severe regulatory actions, most notably Trip.com's $763M penalty from China's SAMR, and a string of failed or abandoned deals (Onfolio/Paramount, IMAQ's 20th extension). Financial results are mixed: Ensign Group posted strong 17.3% revenue growth and raised guidance, while Ladder Capital saw net income fall 15.8% YoY. Insider activity is sparse but notable, with United Therapeutics' CEO selling $1.45M and Greenwich LifeSciences' CEO making small insider purchases. The forward-looking landscape is rich with catalysts, including AstraZeneca's mixed Phase III readouts and Apnimed's upcoming IPO, suggesting a high-conviction but risk-aware environment.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — July 27, 2026

The two filings for July 27, 2026, both involve amended Schedule 13G filings from major institutional investors (JPMorgan and BlackRock) in S&P 500 Consumer Discretionary companies (AutoZone and Chipotle). These are passive, non-control filings, indicating that large asset managers are maintaining or adjusting significant stakes in the sector. The filings show no insider trading activity, no guidance changes, and no capital allocation events, suggesting a period of stability for these two companies. The overall sentiment is neutral, with no immediate bullish or bearish catalysts. The key takeaway is that institutional ownership remains high, signaling confidence in the long-term value of these consumer discretionary names, but without any period-over-period trends or forward-looking data to drive active trading decisions.

2 medium 2 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — July 27, 2026

The three S&P 500 Healthcare filings on July 27, 2026, reveal a sector bifurcated between strategic restructuring and governance tightening. Boston Scientific’s massive $700-800M restructuring plan signals a proactive push for cost efficiencies and reinvestment, aiming for $500M in annual savings by 2029, though near-term cash outflows and headcount reductions create execution risk. Intuitive Surgical’s bylaw amendments, while non-financial, indicate a defensive posture against activist stockholders and complex ownership structures, a theme growing across large-cap medtech. Edwards Lifesciences presents a clear insider concern: the CEO sold $245K in stock and made gifts, a bearish signal given the lack of disclosed positive catalysts. No period-over-period revenue or margin trends were available from these filings, but the aggregate insider activity and restructuring magnitude suggest a sector focused on operational resilience rather than aggressive growth. The lack of forward-looking guidance from Intuitive and Edwards leaves Boston Scientific as the sole catalyst-rich name, with its restructuring timeline extending to 2029.

3 high priority 3 total filings
· daily

US Earnings Financial Results SEC Filings — July 27, 2026

The 24 filings reveal a bifurcated earnings landscape: revenue growth is robust across many sectors (e.g., Ensign Group +17.3%, FirstCash +29.4%, Celestica +62.4%), but profitability and cash flow tell a more cautious story. A clear theme of 'growth at a cost' emerges, with several companies (Sanmina, Clean Energy Technologies, Champions Oncology) reporting surging revenues alongside margin compression, widening losses, or negative operating cash flow. Insider trading activity is notably absent from most filings, but capital allocation patterns are stark: aggressive M&A (Ensign, Sanmina) and share buybacks (Cincinnati Financial, FirstCash) are common, while several firms are burning cash (Navitas, GeoVax). The commercial real estate and insurance sectors show mixed signals, with Ladder Capital and Brixmor facing rising expenses and impairment charges. Overall, the market is rewarding top-line growth but punishing companies that fail to convert it into sustainable earnings and cash generation.

24 high priority 24 total filings
· daily

US Executive Compensation Proxy SEC Filings — July 27, 2026

The six proxy filings reveal a bifurcated executive compensation landscape, with Take-Two Interactive emerging as a standout due to its massive operational inflection point, while smaller firms like LiveOne and Sow Good face governance and pay-for-performance misalignments. Period-over-period data shows Take-Two's Net Bookings surged to $6.72B, exceeding initial guidance by ~$750M, signaling a powerful growth cycle driven by GTA VI. Conversely, LiveOne's PEO compensation remained flat at ~$560K, but average non-PEO NEO pay dropped 23% YoY to $205K, indicating equity value erosion and potential retention risk. Dorian LPG and Viasat present routine governance with no material financial trends, while LIXTE (now Nomad Power Solutions) carries high risk due to a post-merger conversion vote that could trigger a 7% cumulative dividend if not approved. The overarching theme is a divergence between high-growth, catalyst-rich firms and those navigating structural or governance overhangs.

6 high priority 6 total filings
· daily

US IPO Pipeline SEC S-1 Filings — July 27, 2026

The IPO Pipeline digest for July 27, 2026, reveals a bifurcated market: one established financial firm (Jones Financial) is restructuring its capital structure without a public listing, while two smaller, high-risk entities (AIxCrypto and OppFi) pursue transformative transactions to access public markets or expand via M&A. Period-over-period trends are limited as these are initial filings, but forward-looking data and transaction details highlight significant execution risk. AIxCrypto, with no material revenue, is pivoting to RWA tokenization and Embodied AI, relying on a $50 million equity facility—a high-risk, high-reward play. OppFi's merger with BNCC offers a fixed exchange ratio that creates valuation uncertainty for BNCC shareholders, though it targets a tax-free reorganization. No insider trading activity was reported in any filing, and capital allocation data is sparse, underscoring the early-stage nature of these deals. The overarching theme is capital structure transformation, with materiality ranging from moderate (Jones) to very high (OppFi), but all carry execution and regulatory risks.

3 high priority 3 total filings
· daily

US SEC Trading Suspension Halt Orders — July 27, 2026

Three micro-cap companies face acute regulatory and listing crises on US exchanges, signaling a severe liquidity and compliance crunch in the small-cap space. All three filings (AMASS Brands, Nexalin Technology, Picard Medical) report negative sentiment and high materiality (8-9/10), with two facing imminent trading suspension or delisting. Period-over-period data reveals a common pattern: deteriorating equity bases (Picard Medical swung from $3.8M equity to a $(1.4)M deficit QoQ) and sustained market value erosion (AMASS Brands failed the $50M MVLS threshold for 30+ days). No insider buying or positive forward guidance exists across any filing, while capital allocation is absent (no dividends, buybacks, or M&A). The cluster of delisting events within a single week (July 22-24, 2026) suggests a broader regulatory tightening or sector-wide distress. Investors should treat these names as high-risk, with Nexalin's August 4 suspension date being the most immediate catalyst.

3 high priority 3 total filings
· daily

US Executive Officer Management Changes SEC — July 27, 2026

This digest covers 24 SEC filings from July 27, 2026, focusing on executive and director changes. The most critical development is the CEO succession at Sarepta Therapeutics, where a highly experienced biopharma leader takes over, signaling a potential strategic shift. Another high-impact event is the appointment of a new CEO at Power Solutions International, following a comprehensive search, which could mark a turnaround. The acquisition-led appointment at Profusa, Inc. and the CEO change at Cracker Barrel are also notable. Across the filings, there is a clear trend of companies appointing directors with deep operational and financial expertise, particularly in data centers, energy, and transportation. Insider trading activity is absent from these filings, but forward-looking statements, such as the expected system integration at Independent Bank Corp, provide actionable timelines. The overall sentiment is mixed to positive, with a focus on strengthening leadership teams for growth and operational excellence.

24 high priority 24 total filings
· daily

USA Insider Trading Pulse — July 27, 2026

The July 27, 2026 insider trading pulse reveals a market characterized by starkly divergent management actions. While a few significant insider purchases signal strong conviction in specific names like **Jefferies Credit Partners BDC** and **Greenwich LifeSciences**, the dominant theme is a wave of high-value, pre-planned insider selling by top executives at major companies. Notable sales by the CEO of **United Therapeutics** ($1.45M) and the CFO of **Hancock Whitney** ($1.73M) create a bearish undercurrent, particularly in the financial sector. A significant cluster of insider selling is also observed at **Opus Genetics**, where four top executives sold shares simultaneously, raising a major red flag. The day was also heavy with neutral, routine equity awards and tax-withholding transactions, which provide little directional signal but confirm standard compensation practices. The most actionable intelligence lies in the contrast between the large, strategic insider buying and the coordinated selling events, pointing to specific opportunities and risks for investors.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — July 27, 2026

The July 27, 2026 M&A landscape is dominated by two significant completed acquisitions (Lattice Semiconductor/AMI and Novanta/Riverpoint Medical) that are expected to be immediately accretive to margins and earnings, signaling strong strategic execution in the semiconductor and medtech sectors. However, the SPAC market continues to show severe distress: Future Vision II Acquisition Corp. faces a massive 65% public share redemption despite overwhelming shareholder approval, while International Media Acquisition Corp. is burning through its final permitted extensions with no target in sight. A new cross-border deal from AiRWA Inc. introduces diversification but carries execution risk, and Translational Development Acquisition Corp. is still awaiting SEC effectiveness for its combination with ProLogium. Period-over-period trends from the enriched data reveal a clear bifurcation: operating companies are delivering accretive, value-creating M&A, while blank-check companies are struggling with redemptions, deadline pressures, and regulatory delays. Insider activity is absent across these filings, but forward-looking guidance from Lattice and Novanta points to strong revenue and earnings catalysts in early August.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — July 27, 2026

Overnight filings reveal a market bifurcated between aggressive capital deployment (M&A, buybacks, spin-offs) and significant regulatory/pipeline setbacks. The most critical development is the $2.2B acquisition of Forte Biosciences by argenx at an 86% premium, signaling high conviction in the autoimmune space. However, this is contrasted by Trip.com's $781M anti-monopoly penalty in China and AstraZeneca's dual pipeline outcomes (positive gastric cancer data, failed HSCT-TMA trial). From a period-over-period perspective, Ensign Group and Baker Hughes show operational strength with 17.3% and 2% sequential revenue growth respectively, while Ladder Capital and Clean Energy Technologies show deteriorating profitability (net income down 15.8% YoY and gross profit swing to loss). Insider activity is mixed: a CEO purchase at Greenwich LifeSciences contrasts with a CEO sale at United Therapeutics. Capital allocation is active, with Flex Ltd. pursuing a spin-off and multiple buyback programs (BBVA, Prudential, Ryanair). The overall theme is one of strategic repositioning, with companies pivoting into new sectors (NIMU to space, Twenty One Capital to Bitcoin operating model) while others face existential regulatory or financial headwinds (Trip.com, International Media Acquisition). The breadth of filings suggests a market actively seeking growth vectors amid a complex macro environment.

17 high priority 33 medium 50 total filings